Pyxis Oncology Statistics

Total Valuation

Pyxis Oncology has a market cap or net worth of $255.21 million. The enterprise value is $154.02 million.

Market Cap	255.21M
Enterprise Value	154.02M

Important Dates

The next estimated earnings date is Thursday, May 9, 2024, before market open.

Earnings Date	May 9, 2024
Ex-Dividend Date	n/a

Share Statistics

Pyxis Oncology has 58.13 million shares outstanding. The number of shares has increased by 20.80% in one year.

Shares Outstanding	58.13M
Shares Change (YoY)	+20.80%
Shares Change (QoQ)	+7.62%
Owned by Insiders (%)	20.49%
Owned by Institutions (%)	29.90%
Float	35.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	55.21
PB Ratio	2.02
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.84, with a Debt / Equity ratio of 0.17.

Current Ratio	4.84
Quick Ratio	n/a
Debt / Equity	0.17
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -52.60% and return on invested capital (ROIC) is -55.90%.

Return on Equity (ROE)	-52.60%
Return on Assets (ROA)	-41.10%
Return on Capital (ROIC)	-55.90%
Revenue Per Employee	n/a
Profits Per Employee	-$1.48M
Employee Count	50
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +42.38% in the last 52 weeks. The beta is 1.51, so Pyxis Oncology's price volatility has been higher than the market average.

Beta (1Y)	1.51
52-Week Price Change	+42.38%
50-Day Moving Average	5.14
200-Day Moving Average	2.94
Relative Strength Index (RSI)	42.52
Average Volume (30 Days)	805,246

Short Selling Information

The latest short interest is 2.21 million, so 3.80% of the outstanding shares have been sold short.

Short Interest	2.21M
Short Previous Month	2.70M
Short % of Shares Out	3.80%
Short % of Float	6.24%
Short Ratio (days to cover)	2.52

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-82.20M
Pretax Income	-73.79M
Net Income	-73.79M
EBITDA	-71.20M
EBIT	-73.79M
Earnings Per Share (EPS)	-$1.85

Full Income Statement

Balance Sheet

The company has $120.77 million in cash and $21.33 million in debt, giving a net cash position of $99.44 million or $1.71 per share.

Cash & Cash Equivalents	120.77M
Total Debt	21.33M
Net Cash	99.44M
Net Cash Per Share	$1.71
Equity / Book Value	125.70M
Book Value Per Share	2.16
Working Capital	98.85M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$70.71 million and capital expenditures -$6.73 million, giving a free cash flow of -$77.44 million.

Operating Cash Flow	-70.71M
Capital Expenditures	-6.73M
Free Cash Flow	-77.44M
FCF Per Share	-$1.94

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Pyxis Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.80%
Shareholder Yield	-20.80%
Earnings Yield	-29.11%
FCF Yield	-30.55%

Analyst Forecast

The average price target for Pyxis Oncology is $9.80, which is 122.47% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.80
Price Target Difference	122.47%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-2.72%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1